Technology-driven early-stage detection and therapeutic support tools for ADHD, ASD, Alzheimer's Disease. CE Marked.
Technology-driven early-stage detection and therapeutic support tools for ADHD, ASD, Alzheimer's Disease. CE Marked.
Founded: 2013 (University of Barcelona spin-off)
Product focus: Eye-tracking diagnostic & digital therapeutic tools (BGaze Clinic, BGaze Therapy/Focus)
Regulatory status: CE marked
Recent funding: Venture round announced Mar 6, 2024
Headcount (reported): 6
Diagnostic assessment, monitoring, and digital therapeutic support for neurodevelopmental and neurocognitive disorders.
2013
Medtech / Digital Therapeutics
“Lead investor reported for most recent venture round: RYSE Asset Management”